Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
Our survey highlights the importance of allowing CDK4/6i switching, thus likely prompting oncologists to adapt their treatment choices, leading to better AEs management for improving patients' outcome.
Authors
- Carmen Criscitiello (ORCID: https://orcid.org/0000-0001-9064-0113)
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Massimo Di Maïo (ORCID: https://orcid.org/0000-0001-8906-3785)
- Paola Zagami (ORCID: https://orcid.org/0000-0002-2687-6436)
- Pier Paolo Maria Berton Giachetti (ORCID: https://orcid.org/0000-0001-5559-7279)
- Beatrice Taurelli Salimbeni (ORCID: https://orcid.org/0000-0002-7345-4148)
- Roberta Scafetta
- Matteo Lambertini (ORCID: https://orcid.org/0000-0003-1797-5296)
- Angela Espósito
- Saverio Cinieri (ORCID: https://orcid.org/0009-0009-1440-7278)
Institutions
- Università Campus Bio-Medico (IT)
- Ospedale A. Perrino (IT)
- A. O. Ordine Mauriziano di Torino (IT)
- Ospedale Policlinico San Martino (IT)
- University of Turin (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- The Breast
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1016/j.breast.2025.103875
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 4.56